In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 96 for your search:
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  advanced adult primary liver cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: ONC-2010-19, NCT01203787
2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-045, NCT01347333
3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA182-037, EUDRACT # 2008-008715-26, NCT00908752
4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01989, CALGB 80802, CDR0000659348, U10CA031946, NCT01015833
5.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: POLARIS2009-001, NCT01287585
6.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TS-103, NCT01556490
7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ197-A-U303, NCT01755767
8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-352, NCT00516165
9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683
10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 04-101, R01 CA104524, NCT00669136
11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 062010-150, NCT01264705
12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7050-701, 2011-000752-41, NCT01271504
13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
14.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000720022, NCCTG-N1153, N1153, NCT01497444
15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 12D.424, NCT01754987
16.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130046, 13-C-0046, NCT01766635
17.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J0598, JHOC-NA_00001249, NCT00335829
18.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00224, PHII-83, N01CM62209, CDR0000538220, CCC-PHII-83, 7792, UPCC-UPCI-06-099, 06-099, NCT00459108
19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 1365-002, P30CA060553, NCT00532740
20.

Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: GRID, NCT00765570
21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 08-256, K23CA139005, IST000508, NCT00813293
22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 101282, MUSC-101282, GENENTECH-AVF4481s, NCT00881751
23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PRO08070016, NCT00877071
24.

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: STU 12339, P30CA060553, STU# 00012339, CDR0000651416, NU-09I2, IRB# STU00012339, NCT00956930
25.

Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02086, MC0845, N01CM00100, N01CM00099, N01CM00038, N01CM00071, N01CM00070, N01CM00032, CDR0000653790, MAYO-MC0845, 8233, NCT01010126
1     
New Search